share_log

At US$227, Is STERIS Plc (NYSE:STE) Worth Looking At Closely?

At US$227, Is STERIS Plc (NYSE:STE) Worth Looking At Closely?

STERIS Plc(紐約證券交易所代碼:STE)的價格爲227美元,值得仔細研究嗎?
Simply Wall St ·  05/24 21:27

Today we're going to take a look at the well-established STERIS plc (NYSE:STE). The company's stock saw a double-digit share price rise of over 10% in the past couple of months on the NYSE. Shareholders may appreciate the recent price jump, but the company still has a way to go before reaching its yearly highs again. As a large-cap stock with high coverage by analysts, you could assume any recent changes in the company's outlook is already priced into the stock. However, what if the stock is still a bargain? Let's take a look at STERIS's outlook and value based on the most recent financial data to see if the opportunity still exists.

今天我們將來看一下已經成熟的思泰瑞醫療(NYSE:STE)公司。該公司的股票在紐交所過去幾個月中漲幅超過10%。 股東們可能會欣賞最近的股價上漲,但該公司仍有一定的發展空間。 作爲一家高度受到分析師關注的大市值股票,你可以假設公司最近的前景變化已經被反映在股票價格中。 然而,如果股票仍處於低價區間呢?讓我們看看思泰瑞醫療的前景和價值,以了解機會是否仍然存在。

What's The Opportunity In STERIS?

思泰瑞醫療的機會在哪裏?

Great news for investors – STERIS is still trading at a fairly cheap price. Our valuation model shows that the intrinsic value for the stock is $297.82, but it is currently trading at US$227 on the share market, meaning that there is still an opportunity to buy now. Another thing to keep in mind is that STERIS's share price may be quite stable relative to the rest of the market, as indicated by its low beta. This means that if you believe the current share price should move towards its intrinsic value over time, a low beta could suggest it is not likely to reach that level anytime soon, and once it's there, it may be hard to fall back down into an attractive buying range again.

對於投資者來說,這是個好消息——思泰瑞醫療的股票仍然以相對便宜的價格交易。 我們的估值模型顯示,該股票的內在價值爲297.82美元,但目前在股票市場上以227美元的價格交易,這意味着現在仍有購買機會。 另一個需要記住的事情是,相對於市場其他部分,思泰瑞醫療的股價可能相當穩定,這可以通過其低beta值來說明。這意味着,如果您認爲當前股價應該隨着時間推移向其內在價值接近,低beta可能表明它不太可能在短時間內達到該水平,一旦達到該價值,再次回落到一個有吸引力的購買區間可能會很難。

Can we expect growth from STERIS?

我們能否從思泰瑞醫療中期待增長?

earnings-and-revenue-growth
NYSE:STE Earnings and Revenue Growth May 24th 2024
NYSE: STE的盈利和營業收入增長情況於2024年5月24日

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. STERIS' earnings over the next few years are expected to increase by 70%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.

尋找投資組合增長的投資者可能需要在購買該公司的股票之前考慮該公司的前景。 以便宜的價格購買前景良好的公司總是一個不錯的投資,因此讓我們也來看一下該公司的未來預期。預計未來幾年思泰瑞醫療的收益將增加70%,表明它有一個非常積極的未來。這應該導致更強健的現金流,進而推高股票價值。

What This Means For You

這對您意味着什麼?

Are you a shareholder? Since STE is currently undervalued, it may be a great time to increase your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation.

你是一位股東嗎?由於現在STE的價值被低估,現在增加持股可能是一個很好的時機。有一個樂觀的前景,似乎這種增長還沒有完全反映在股價中。但是,還有其他因素,例如資本結構需要考慮,這可以解釋目前的低估。

Are you a potential investor? If you've been keeping an eye on STE for a while, now might be the time to make a leap. Its prosperous future outlook isn't fully reflected in the current share price yet, which means it's not too late to buy STE. But before you make any investment decisions, consider other factors such as the strength of its balance sheet, in order to make a well-informed buy.

你是一位潛在的投資者嗎?如果你一直在關注STE,現在可能是一個跨越的時機。其繁榮的未來前景尚未完全反映在當前的股價中,這意味着現在購買STE還不算太晚。但是,在做出任何投資決策之前,考慮其他因素,例如其資產負債表的強勁程度,以做出明智的購買。

So while earnings quality is important, it's equally important to consider the risks facing STERIS at this point in time. Every company has risks, and we've spotted 2 warning signs for STERIS you should know about.

因此,儘管收益質量很重要,但在考慮STIRIS面臨的風險時,同樣重要的是。每個公司都有風險,我們已經發現了2個STIRIS的警告信號,您應該了解。

If you are no longer interested in STERIS, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

如果你不再對思泰瑞醫療感興趣,可以使用我們的免費平台查看我們的另外50多隻具有高增長潛力的股票列表。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論